Showing results (1-10 of 108) with videos related to
Sort By:
Pageof 11
Open Medicine (Warsaw, Poland)|November 19, 2019
Prognostic Significance of CD276 in Non-small Cell Lung CancerChanggong Zhang, Xuezhi HaoOpen Medicine (Warsaw, Poland)|July 2, 2019
Expression of CENPE and its Prognostic Role in Non-small Cell Lung CancerXuezhi Hao, Tao QuFrontiers in Pharmacology|July 22, 2021
Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung CancerXuezhi Hao, Aizong Shen, Bin WuFrontiers in Oncology|November 21, 2022
Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysisPuyuan Xing, Xuezhi Hao, Xin Zhang, et al.Annals of Palliative Medicine|January 12, 2022
Clinical value of serum albumin level in patients with non-small cell lung cancer and anaplastic lymphoma kinase (ALK) rearrangementXin Zhang, Puyuan Xing, Xuezhi Hao, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 17, 2018
[Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer]Xin Zhang, Puyuan Xing, Xuezhi Hao, et al.Thoracic Cancer|June 1, 2017
Use of microwave ablation in the treatment of patients with multiple primary malignant tumorsYue Han, Na Shao, Xiaoming Xi, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 21, 2012
[Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer]Junling Li, Jing Wang, Xuezhi Hao, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Nimotuzumab Combined with Chemotherapy as Second- or Later-line in the Treatment of Advanced Lung Squamous Cell Carcinoma]Yang Luo, Junling Li, Yan Wang, et al.Oncotarget|November 12, 2016
Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastasesPuyuan Xing, Shouzheng Wang, Xuezhi Hao, et al.Pageof 11